Role Description

We are seeking a Senior Scientist to join our team in a full-time role. The scientist will work in a small team setting to develop and improve our platform for drug discovery of gene regulators. We are looking for a technology leader interested in developing and applying new proteomics technologies to solve complex biological problems who are interested in working in a fast-paced, innovative, early-stage biotech environment.

Responsibilities

  • Experimental design and laboratory execution of biochemical and mass spectrometry-based assays including proteomics data processing, visualization, and biological interpretation
  • Protein isolation from mammalian cells and peptide preparation for mass spectrometry
  • Routine usage of Thermo Orbitrap mass spectrometers with HPLC separation and high-throughput quantitative proteomics methodologies
  • Mass spectrometry data analysis using bioinformatics software including R and/or Python
  • Conduct independent research and demonstrate scientific leadership within the project team and across departments; Collaborate with all the functions within the Company to advance our science
  • Accurately document experiments and results in electronic laboratory notebooks in a timely fashion
  • Maintain a safe and productive laboratory environment
  • Prepare and present experimental results, analysis, and plans in R&D meetings

Qualifications

Required

  • The successful candidate will have a PhD with 0-3 or BS/MS degree with 5-7 years of industry experience developing and analyzing quantitative mass spectrometry proteomics assays
  • Familiarity with proteomics raw data processing, interpretation, and visualization
  • Familiarity with Thermo instrument software (XCalibur, Tune) as well as Skyline
  • Experience with LCMS method development, maintenance, and troubleshooting
  • Understanding of best practices for proteomic sample handling and preparation
  • Ability to deliver complex results to teams of diverse scientific backgrounds
  • Ability to work effectively and collaboratively on cross-functional projects teams
  • Excellent oral, presentation, and written communication skills

Preferred

  • Experience working with Data-Independent Acquisition (DIA) proteomics data
  • Familiarity with AWS cloud data processing pipelines and/or the WDL or NextFlow computational biology pipeline languages
  • Familiarity with cancer biology and/or drug discovery

About Talus Bio

Therapeutic development is on the verge of a revolution. The tools of genome sequencing have helped us discover which proteins are best to target across countless diseases. The problem is that most of these top-tier targets have been written off as undruggable because they don't fit into the "standard" experimental models developed by the pharmaceutical industry. Fundamental breakthroughs in proteomics technology being developed at Talus will allow us to unlock many of these targets for the first time.

Talus Bio's vision is to build a tech-bio therapeutics engine that will unlock the genome regulatory network (the "regulome") for systematic drug development. The regulome is responsible for interpreting the human genome by switching genes on and off at the correct time in the correct cells, and their malfunction is common across many diseases. Currently, less than 20 regulome targets have been drugged, leaving over 400 targets left to be addressed in cancer alone.

Our platform measures a drug’s ability to disrupt a gene regulator within its natural, non-engineered cellular environment. Furthermore, a single experiment using the platform measures activity for hundreds of gene regulators simultaneously, providing information on in-cell drug activity and specificity in a single experiment. To accomplish this, we combine innovative cell processing with high-sensitivity quantitative proteomics and advanced downstream analytics.

The science on which the company was founded was developed at the Altius Institute for Biomedical Research and the University of Washington in Seattle. The initial work was published in Cell Reports in 2020- and further written up in FierceBiotech. Talus Bio's investors include leading venture funds (including NFX, Fifty Years, FundersClub, Pioneer Fund, Axial, Boom Capital, and others), as well as grant support from the National Science Foundation.